Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05575037 · ClinicalTrials.gov registry record · Phase 2
Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease
A Phase 2 study of Nasal Polyps and Aspirin-exacerbated Respiratory Disease, sponsored by Brigham and Women's Hospital.
- Active
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT05575037 is a Phase 2 study of Nasal Polyps and Aspirin-exacerbated Respiratory Disease that is active but no longer recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 17 participants, below the 100-participant average among 7 other Nasal Polyps trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05575037, a Phase 2 study of Nasal Polyps and Aspirin-exacerbated Respiratory Disease, is active but no longer recruiting, sponsored by Brigham and Women's Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall aim of the study is to determine the clinical efficacy and mechanisms of action of anti-IL-4a (dupilumab) as treatment for patients with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) and Aspirin-Exacerbated Respiratory Disease (AERD).
Conditions Studied
Interventions
- DRUG Dupilumab
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2023-08-01 |
| Est. Completion | 2026-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05575037
The ClinicalTrials.gov registry entry for NCT05575037 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 100-participant average among 7 other Nasal Polyps trials with a reported enrollment target (83% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Nasal Polyps appearing as the primary indexed condition, and to 1 intervention - of which Dupilumab is the first listed.
NCT05575037 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05575037 about?
NCT05575037 is a clinical study titled "Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease". The overall aim of the study is to determine the clinical efficacy and mechanisms of action of anti-IL-4a (dupilumab) as treatment for patients with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) and Aspirin-Exacerbated Respiratory Disease (AERD).
What is the current status of trial NCT05575037?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2023-08-01. Estimated completion is 2026-04-30.
What conditions does trial NCT05575037 study?
This clinical trial studies the following conditions: Nasal Polyps, Aspirin-exacerbated Respiratory Disease, Asthma, Aspirin-Induced, Aspirin-Sensitive Asthma With Nasal Polyps.
What interventions are being tested in trial NCT05575037?
The interventions under investigation include: Dupilumab (DRUG).
Who is sponsoring clinical trial NCT05575037?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05575037 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nasal Polyps
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Does Batten Grafting Improve Nasal Outcomes in Septoplasty and Turbinate Reduction?
RECRUITING · NA
-
Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP
RECRUITING · Phase 4
-
Dupixent Study for Alternate Administration
ACTIVE NOT RECRUITING · Phase 4
-
Comparing Blood Loss and Visualization After the Preoperative Use of Topical 0.05% Oxymetazoline Versus 1:1000 Epinephrine Prior to Endoscopic Sinus Surgery
COMPLETED · Phase 4
-
The Polymerase Chain Reaction (PCR) Analysis of Nasal Polyps for Fungal DNA
COMPLETED · NA
-
Qualitative Analysis of Subject Experience of Nasal Polyps
COMPLETED
Explore more on PlainTrial
Nasal Polyps
All registered trials for this condition
Aspirin-exacerbated Respiratory Disease
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.